Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DF9001,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Dragonfly Therapeutics Collaborates to Evaluate DF9001 with KEYTRUDA® in Solid Tumors
Details : Through the collaboration, DF9001 Dragonfly's EGFR immune engager, in combination with Merck's anti-PD-1 therapy, Keytruda in patients with advanced solid tumors.
Product Name : DF9001
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
May 21, 2024
Lead Product(s) : DF9001,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Dragonfly Receives Milestone Payment After Dosing First Patient in AbbVie Phase 1 Trial
Details : The collaboration aims to focus on the development of ABBV-303 in combination with ABBV-181, which is being evaluated in the Phase I clinical trial studies for the treatment of neoplasms.
Product Name : ABBV-303
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 03, 2024
Lead Product(s) : Df1001,Sacituzumab Govitecan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Dragonfly Explores DF1001 with Gilead's Trodelvy® in Cancer Combinations
Details : The collaboration aims to combine DF1001, targeting NK cells and T-cell activation, with Gilead's Trop-2 antibody-drug conjugate for treating breast and lung cancers.
Product Name : DF1001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 15, 2024
Lead Product(s) : Df1001,Sacituzumab Govitecan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : DF6002,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DF6002 is a monovalent IL12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.
Product Name : DF6002
Product Type : Protein
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : DF6002,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dragonfly lead product candidate DF6215, which is IL-2 Immunotherapy. Currently, it is being evaluated in the clinical development with patients for the treatment of advanced solid tumors.
Product Name : DF6215
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : Df1001,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET®
Details : The Company’s first TriNKET, DF1001, entered Phase 2 trials this month after being well-tolerated in Phase 1 with encouraging clinical responses, including showing tumor burden reductions across several tumor types, including in HER2-low and heavily pr...
Product Name : DF1001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Df1001,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Df1001,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DF1001 was well-tolerated with no dose limiting toxicities during dose escalation in the Phase 1 study. The study showed encouraging pharmacodynamic effects including infiltration of NK cells and T cells into tumors.
Product Name : DF1001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 12, 2022
Lead Product(s) : Df1001,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DF7001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Gilead will receive an exclusive, worldwide license from Dragonfly for the 5T4-targeting investigational immunotherapy, DF7001. Gilead also gains worldwide rights to develop and commercialize NK cell engager programs using the Dragon...
Product Name : DF7001
Product Type : Cell and Gene therapy
Upfront Cash : $300.0 million
February 05, 2022
Lead Product(s) : DF7001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : MK-4464,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target
Details : Under the agreement Merck has exercised its option to license exclusive worldwide intellectual property rights on its second immunotherapy candidate DF8001 (MK-4464), developed using the TriNKET™ technology platform.
Product Name : DF8001
Product Type : Antibody
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : MK-4464,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : DF6002,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DF6002/BMS-9896415, a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong anti-tumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive anti-tumor responses.
Product Name : DF6002
Product Type : Protein
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : DF6002,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable